Although patients with other solid tumors have benefited from immune checkpoint blockade therapy targeting the PD1/PD-L1 interaction, CRC patients did not benefit until the introduction of the concept of mismatch repair (MMR) proficiency or deficiency [7, 8]. This evidence concerns the gene CD274 and colorectal carcinoma.